Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313416 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and CT-011 for Resected Pancreatic Cancer
A Phase 2 study, sponsored by Augusta University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01313416 is a Phase 2 study that was terminated before completion, run by Augusta University. The registered enrollment target is 2 participants.
The verdict
NCT01313416, a Phase 2 study, was terminated before completion, sponsored by Augusta University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Background: * In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%. * Many doctors believe that individuals who have had surgery to remove pancreatic cancer should receive additional treatment, known as adjuvant therapy or adjuvant treatment, to prevent the cancer from returning. One chemotherapy drug that has been found to be effective in some patients with pancreatic cancer is called gemcitabine; it has been shown to improve patient survival by 6 months. Researchers are searching for new drugs or drug combinations to improve on these results. * One of the leading causes for immune suppression in cancer patients was suggested to be associated with the elevated expression of programmed cell death ligand 1 (PD-L1) human B7 homolog 1 (B7-H1) at tumor-involved sites, either by the tumor itself or by surrounding cells like regulatory immune cells, resulting in the local suppression and apoptosis of tumor infiltrating effector lymphocytes. * Some chemotherapy drugs kill cancer cells directly, but appear to prevent the immune system from helping in that fight. The experimental drug CT-011 is designed to help the immune system remain active to fight cancer cells. CT-011 has been tested in laboratories and studied for use with a number of other cancers, but it has not been given in combination with gemcitabine as a treatment for pancreatic cancer. Objective: \- To test the safety and effectiveness of chemotherapy drugs gemcitabine and CT-011 as a follow-up treatment for pancreatic cancer that has been surgically removed. Eligibility: \- Individuals at least 18 years of age who have had surgery to remove pancreatic cancer and have not had other types of follow-up treatments. Design: * Participants will receive gemcitabine and CT-011 in 28-day cycles of treatment, and will be monitored throughout their treatment. * Participants who do not have serious side effect
Interventions
- DRUG Gemcitabine
- BIOLOGICAL CT-011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313416
The ClinicalTrials.gov registry entry for NCT01313416 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01313416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313416 about?
NCT01313416 is a clinical study titled "Gemcitabine and CT-011 for Resected Pancreatic Cancer". Background: * In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%. * Many doctors believe that individuals who have had surgery to remove pancreatic cancer should receive additional treatmen...
What is the current status of trial NCT01313416?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-09. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01313416?
The interventions under investigation include: Gemcitabine (DRUG), CT-011 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01313416?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.